CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab : Melanoma Research

Journal Logo

You can read the full text of this article if you:

Access through Ovid
Original Articles: Translational Research

CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab

Edmonds, Nicole L.a; Flores, Sarah E.a; Mahmutovic, Adelab; Young, Samuel J.c; Mauldin, Ileana S.c,d; Slingluff, Craig L. Jrc,d

Author Information
doi: 10.1097/CMR.0000000000000855
  • Buy
  • SDC

Abstract

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.